CME Idiopathic Pulmonary Fibrosis Survey

Are you a pulmonary/respiratory specialist practicing in the United States? *

Yes

No

How many patients with idiopathic pulmonary fibrosis (IPF) do you see per month (on average) *

Less than 5

6 – 10

More than 10

Of your patients with an IPF diagnosis, how many are being treated with pirfenidone? *

Of your patients with an IPF diagnosis, how many are being treated with nintedanib? *

Of your patients with an IPF diagnosis, how many are being treated with prednisone, azathioprine and NAC combination therapy? *

Of your patients with an IPF diagnosis, how many are being treated with a PPI? *

Of your patients with an IPF diagnosis, how many have undergone genetic testing (either TOLLIP or MUC5B)? *

Please rate your degree of familiarity with molecular biomarkers for prediction of IPF prognosis: *

Not at all familiar

Somewhat familiar

Very familiar

Extremely familiar

Please rate your degree of familiarity with the 2015 ATS/ERS/JRS/ALSAT guidelines for the treatment of IPF: *

Not at all familiar

Somewhat familiar

Very familiar

Extremely familiar

For your patients receiving pirfendone or ninetanib, which of the following led to your decision? *

Current guideline recommendations

Evidence from clinical trials supporting their use in IPF

Patient request

Available reimbursement

For your patients on agents other than pirfendone or ninetanib, which of the following led to your decision? *

Disagree with or not aware of current guideline recommendations

Unaware of data supporting their use in IPF

Patient refusal

Cost

You are here